ClinicalTrials.gg
RecruitingNCT07622524Updated Aug 14, 2026

A Phase I Study of CS5007 in Participants With Advanced Solid Tumors

A Phase 1 interventional study of CS5007 in Advanced Solid Tumors, sponsored by CStone Pharmaceuticals. Recruiting at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by CStone Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
310
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a first-in-human (FIH), open-label, and multi-center Phase I study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS5007 as monotherapy in participants with advanced solid tumors. The study is comprised of a Phase Ia dose escalation and Phase Ib dose expansion.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • EGFR
  • HER3
  • Bispecific Antibody-Drug Conjugate
  • Phase I
  • Advanced Solid Tumors
03

In context

Lead sponsor

CStone Pharmaceuticals is the lead sponsor of 29 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Evidence of a personally signed and dated document.
  • Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • Being ≥ 18 years of age on the day of signing informed consent.
  • or cytologically confirmed, unresectable advanced solid tumors.
  • Participants must have at least one according to Version1.1.
  • (ECOG) Performance Score of 0 or 1.
  • Adequate organ function.
  • ≥ 3 months.
  • Fertile men and women of must agree to use an effective method of from providing signed consent and for 180 days after the last study drug administration

Exclusion criteria

Exclusion Criteria:

  • Has disease that is suitable for local treatment administered with curative intent.
  • Has a history of a second active within the previous 3 years except for locally curable cancers that have been apparently cured.
  • Known primary central nervous system (CNS) tumor or solid tumor that is symptomatic, untreated, or requires therapy.
  • Has life-threatening bleeding event or severe bleeding within 3 months prior to first dose.
  • Has uncontrolled pleural effusion, pericardial effusion, or ascites.
  • Has immune deficient disease or received systemic treatment.
  • Has intestinal obstruction,or history of inflammatory bowel disease,or chronic diarrhea.
  • Has history of (non-infectious) interstitial lung disease/pneumonitis that required .
  • Has active infections requiring systemic therapy.
  • Has significant cardiovascular disease or cerebrovascular accident within specified timeframes prior to first dose.
  • Insufficient washout from prior anti-tumor therapy.
  • Received within 28 days prior to first dose.
  • History of allogeneic organ or hematopoietic stem cell transplantation.
  • History of to of study drug or any monoclonal antibody.
  • Any toxic effects of prior therapy unresolved to Grade ≤1.
  • Active alcohol or drug abuse.
  • Pregnant or breastfeeding women.
  • Other acute or chronic medical or psychiatric conditions that may increase risk or interfere with study results, in the investigator's judgment.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
310 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    Participants will be administered escalating doses of CS5007.

    Drug: CS5007

  • Experimental
    Dose Expansion

    Participants will be administered the recommended dose(s) of CS5007 according to dose-escalation data.

    Drug: CS5007

Interventions

  • DrugCS5007

    CS5007 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).

06

What researchers measure

Primary outcomes

  1. [Dose Escalation] Maximum tolerated dose (MTD) of CS5007

    Participants will receive CS5007 via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). The MTD will be determined, if any, by the number of participants who experience a dose limiting toxicity (DLT).

    Time frame: Cycle 1 (Up to 21 Days)

  2. [Dose Escalation] Tentative recommended Phase II dose (RP2D) of CS5007

    The selection of tentative RP2D will be based on consideration of overall safety information together with available pharmacokinetic, pharmacodynamic, and efficacy data. The tentative RP2D may be the MTD or a lower dose within the tolerable dose range.

    Time frame: Up to approximately 2 years

  3. [Dose Escalation] The incidence and severity of adverse events (AEs)

    Time frame: Up to approximately 2 years

  4. [Dose Expansion] Objective response rate (ORR) evaluated by investigators per RECIST v1.1

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. [Dose Escalation & Expansion] Area under the curve (AUC) of CS5007

    Time frame: Up to approximately 2 years

  2. [Dose Escalation & Expansion] Maximum concentration (Cmax) of CS5007

    Time frame: Up to approximately 2 years

  3. [Dose Escalation & Expansion] Time to maximum concentration (Tmax) of CS5007

    Time frame: Up to approximately 2 years

  4. [Dose Escalation & Expansion] Elimination half-life (t1/2) of CS5007

    Time frame: Up to approximately 2 years

  5. [Dose Escalation & Expansion] Clearance (CL) of CS5007

    Time frame: Up to approximately 2 years

  6. [Dose Escalation & Expansion] Volume of distribution (Vz) of CS5007

    Time frame: Up to approximately 2 years

  7. [Dose Escalation & Expansion] Trough concentration (Ctrough) of CS5007

    Time frame: Up to approximately 2 years

  8. [Dose Escalation & Expansion] Accumulation ratio (R) of CS5007

    Time frame: Up to approximately 2 years

  9. [Dose Escalation & Expansion] Number of participants with anti-CS5007 antibodies

    Time frame: Up to approximately 2 years

  10. [Dose Escalation] Objective response rate (ORR) evaluated by investigators per RECIST v1.1

    Time frame: Up to approximately 2 years

  11. [Dose Escalation & Expansion] Duration of response (DOR) evaluated by investigators per RECIST v1.1

    Time frame: Up to approximately 2 years

  12. [Dose Escalation & Expansion] Disease control rate (DCR) evaluated by investigators per RECIST v1.1

    Time frame: Up to approximately 2 years

  13. [Dose Expansion] The incidence and severity of adverse events (AEs)

    Time frame: Up to approximately 2 years

07

Study locations

4 of 7 sites recruiting
  • St Vincent's Hospital Sydney
    Darlinghurst, New South Wales 2010, Australia
    Not yet recruiting
    • Jia (Jenny) Liu · Principal investigator
  • Macquarie University
    North Ryde, New South Wales 2109, Australia
    Recruiting
    • Wei Yen Chan · Principal investigator
  • Calvary Mater Newcastle
    Waratah, New South Wales 2298, Australia
    Recruiting
    • Faisal Hayat · Principal investigator
  • Icon Cancer Centre South Brisbane
    South Brisbane, Queensland 4101, Australia
    Recruiting
    • Jermaine Coward · Principal investigator
  • St Vincent's Hospital Melbourne
    Fitzroy, Victoria 3065, Australia
    Not yet recruiting
    • Melissa Moore · Principal investigator
  • Linear Clinical Research Ltd
    Nedlands, Western Australia 6009, Australia
    Recruiting
    • Wee Chin · Principal investigator
  • Shanghai Chest Hospital
    Shanghai, Shanghai Municipality 200030, China
    Not yet recruiting
    • Shun Lu · Principal investigator
    • Ziming Li · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jan 2028, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2026
First posted
Jun 3, 2026
StartActual
Jul 16, 2026
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2029
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07622524
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
Jul 16, 2026
Primary completion
Jan 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Aug 14, 2026

Study contacts

Sean Yao
Contact
yaosheng@cstonepharma.com
+86 18616365940

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion